$BCAX · Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
More about this company
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-03-02 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 11.5% | High | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-03-02 | RA CAPITAL MANAGEMENT, L.P. | director+10%-owner | 300,000 | $4,800,000 | Form 4 |